Trabectedin
- TRADE NAME: Yondelis (Janssen)
- INDICATIONS: Advanced soft tissue sarcoma
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
- HALF-LIFE: 180 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Aprepitant, Atorvastatin, Clarithromycin, Cyclosporine, Fluconazole, Ketoconazole, Phenobarbital, Rifampin, Ritonavir, Rosuvastatin, St John's Wort, Strong CYP3A inducers or inhibitors, Verapamil
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of trabectedin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/27/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
